Democratic Republic of the Congo & Merck & Co.

Democratic Republic of the Congo: The Democratic Republic of the Congo is the epicenter of the Ebola outbreak, facing significant challenges in containment due to conflict, aid cuts, and logistical issues. The outbreak has led to numerous deaths and widespread concern within the country and internationally.

Merck & Co.: Merck & Co. is a key partner in the urgent high-level coordination meeting convened by United States — Centers for Disease Control and Prevention, potentially involved in assessing medical countermeasures for the Ebola outbreak.

Democratic Republic of the Congo: The Democratic Republic of the Congo>>> is the epicenter of the current Ebola outbreak, with hundreds of suspected cases and deaths, facing significant challenges in containment due to conflict, weak health infrastructure, and public mistrust.

Merck & Co.: Merck & Co.>>>'s Ervebo vaccine, effective against the Zaire strain of Ebola, is being considered for potential use against the Uganda — Bundibugyo strain, though its efficacy is still under assessment.

Democratic Republic of the Congo: The Democratic Republic of the Congo is experiencing an outbreak of Ebola Bundibugyo, with 282 confirmed cases and 42 deaths, making it the primary location for vaccine development and trials.

Merck & Co.: Merck & Co.'s approved vaccine Ervebo for the Zaire strain of Ebola is referenced as a technological precedent for IAVI's Bundibugyo vaccine candidate.

Democratic Republic of the Congo: The Democratic Republic of the Congo is experiencing an ongoing outbreak of the Bundibugyo strain of Ebola, leading to the World Health Organization's recommendations for experimental treatments and vaccines.

Merck & Co.: Merck & Co. developed Ervebo, the only licensed Ebola vaccine, which the World Health Organization reviewed but recommended against deploying outside research settings for the Bundibugyo strain due to limited evidence.